La Jolla Pharmaceutical Company (LJPC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
La Jolla Pharmaceutical Company (LJPC) trades at $6.19 with AI Score 63/100 (Grade B+). La Jolla Pharmaceutical Company develops and commercializes therapies for life-threatening diseases, including GIAPREZA for septic shock and XERAVA for complicated intra-abdominal infections. Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for LJPC: LJPC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LJPC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LJPC: 2/3 perspectives are bullish. Dominant signal: Moon AI bullish.
How is this calculated? →La Jolla Pharmaceutical Company (LJPC) Healthcare & Pipeline Overview
La Jolla Pharmaceutical Company develops and commercializes therapies for life-threatening diseases, focusing on critical care and infectious diseases with products like GIAPREZA for septic shock and XERAVA for complicated intra-abdominal infections. The company also maintains an early-stage pipeline targeting multidrug-resistant bacteria and acute myeloid leukemia, operating as a biotechnology entity within the healthcare sector.
What Is the Investment Thesis for LJPC?
La Jolla Pharmaceutical Company presents an operational profile centered on its commercialized critical care assets, GIAPREZA and XERAVA, alongside a strategic early-stage pipeline. The company's financial metrics indicate a P/E ratio of 10.8, a robust gross margin of 82.2%, and a profit margin of 26.0%, reflecting efficiency in its core operations. The high beta of 2.41 suggests significant volatility relative to the broader market, characteristic of the biotechnology sector. Key value drivers include the continued market penetration and adoption of GIAPREZA in the septic shock market and XERAVA in complicated intra-abdominal infections, both addressing critical medical needs. Growth catalysts are primarily tied to the successful advancement of its pipeline candidates—TP-6076, TP-271, and TP-2846—through clinical development, which could unlock new therapeutic areas and revenue streams. Potential risks include the inherent uncertainties of clinical trials, regulatory hurdles for new drug approvals, and intense competition within the biotechnology and pharmaceutical industries. The company's status as a subsidiary of Innoviva, Inc. since August 2022 means its operational performance contributes to the parent company's overall results.
Based on FMP financials and quantitative analysis
LJPC Key Highlights
- Achieved a profit margin of 26.0%, indicating efficient management of operational costs relative to revenue.
- Maintains a strong gross margin of 82.2%, reflecting effective cost control in product manufacturing and sales.
- Trades at a P/E ratio of 10.8, providing a metric for earnings valuation within its sector.
- Exhibits a Beta of 2.41, suggesting higher price volatility compared to the overall market.
- Commercializes two key therapies, GIAPREZA for septic shock and XERAVA for complicated intra-abdominal infections, addressing critical care needs.
Who Are LJPC's Competitors?
LJPC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LJPC's Key Strengths?
- Commercialized products GIAPREZA and XERAVA addressing critical medical needs.
- Strong gross margin of 82.2% and profit margin of 26.0%.
- Diversified early-stage pipeline targeting significant unmet needs in infectious diseases and oncology.
- Strategic licensing agreements for broader market reach.
What Are LJPC's Weaknesses?
- Pipeline candidates are in early-stage development, implying long timelines and high risk.
- High Beta of 2.41 indicates significant market volatility.
- Reliance on a limited number of commercialized products for current revenue.
- Operating as a subsidiary, which may limit independent strategic flexibility.
What Could Drive LJPC Stock Higher?
- **Ongoing**: Continued market penetration and adoption of GIAPREZA for septic or other distributive shock in U.S. hospitals.
- **Ongoing**: Sustained commercial growth and increased utilization of XERAVA for complicated intra-abdominal infections in adult patients.
- **Upcoming**: Progression of early-stage pipeline candidate TP-6076 into more advanced clinical development phases for multidrug-resistant gram-negative bacteria.
- **Upcoming**: Advancement of TP-271 through preclinical or early clinical stages for respiratory diseases caused by bacterial biothreats and resistant pathogens.
- **Upcoming**: Further development milestones for TP-2846 as it progresses in preclinical or early clinical studies for acute myeloid leukemia.
What Are the Key Risks for LJPC?
- Negative return on equity (-25.4%) — the business is not currently generating profit on shareholder capital.
- **Potential**: Clinical trial failures or unexpected safety concerns for early-stage pipeline candidates (TP-6076, TP-271, TP-2846) could halt development and diminish future growth prospects.
- **Ongoing**: Intense competition from existing and emerging therapies in the critical care, infectious disease, and oncology markets, potentially impacting market share and pricing power for GIAPREZA and XERAVA.
- **Potential**: Regulatory delays or non-approval of new drug candidates by health authorities, extending development timelines and increasing costs.
- **Ongoing**: Market access and reimbursement challenges for commercialized products, which could limit adoption rates and revenue growth despite clinical efficacy.
- **Potential**: Dependence on successful execution of licensing agreements with partners like Everest Medicines and PAION AG for global reach and commercialization.
What Are the Growth Opportunities for LJPC?
- **Expanded Market Penetration for GIAPREZA**: GIAPREZA addresses septic or other distributive shock, a critical condition with high mortality rates. Expanding its adoption within hospitals and critical care units across the United States represents a significant growth driver. The market for vasopressors in critical care is substantial, driven by the increasing incidence of sepsis. By demonstrating superior patient outcomes and cost-effectiveness, La Jolla Pharmaceutical can capture a larger share of this market, potentially through enhanced physician education and formulary inclusions. Continued clinical evidence generation and strategic marketing initiatives could solidify GIAPREZA's position as a standard of care, ensuring sustained revenue growth over the next 3-5 years.
- **Increased Adoption of XERAVA for Complicated Intra-abdominal Infections**: XERAVA is indicated for complicated intra-abdominal infections (cIAI), a common and serious condition requiring effective antibacterial treatment, especially given rising antibiotic resistance. The market for cIAI treatments is robust, with a constant need for new and effective agents. La Jolla Pharmaceutical can drive growth by emphasizing XERAVA's efficacy against a broad spectrum of gram-negative and gram-positive bacteria, including multidrug-resistant strains, positioning it as a preferred option in challenging clinical scenarios. Educational outreach to infectious disease specialists and surgeons, coupled with favorable reimbursement policies, could accelerate its market uptake over the medium term (2-4 years).
- **Advancement of TP-6076 for Multidrug-Resistant Gram-Negative Bacteria**: The pipeline candidate TP-6076, an IV fluorocycline derivative, targets multidrug-resistant gram-negative bacteria, a growing global health crisis. The market for novel antibiotics addressing these "superbugs" is characterized by high unmet need and significant potential. Successful progression of TP-6076 through clinical trials, particularly demonstrating efficacy and safety in resistant infections, could position it as a critical therapeutic option. This represents a long-term growth opportunity (5-10 years), with market size potentially in the billions, driven by the urgent need for new antimicrobial agents and government incentives for antibiotic development.
- **Development of TP-271 for Respiratory Pathogens and Biothreats**: TP-271, an IV and oral fluorocycline, is being developed for respiratory diseases caused by bacterial biothreats, antibiotic-resistant public health pathogens, and community-acquired bacterial pneumonia. This broad application addresses both routine and emergency public health needs. The market for respiratory infection treatments is vast, and the specific focus on biothreats and resistant pathogens provides a unique niche. Successful clinical development and potential government contracts for biodefense applications could create a substantial revenue stream. This opportunity is long-term (5-10 years), contingent on clinical success and regulatory approvals, tapping into both commercial and strategic national stockpiling markets.
- **Clinical Progression of TP-2846 for Acute Myeloid Leukemia**: TP-2846, an IV tetracycline, is in development for acute myeloid leukemia (AML), a severe and often rapidly progressing blood cancer with significant unmet needs, particularly for patients who relapse or are refractory to existing therapies. The oncology market, especially for rare and aggressive cancers like AML, commands premium pricing and offers substantial revenue potential for effective treatments. Successful clinical trials demonstrating improved survival or remission rates could position TP-2846 as a valuable addition to AML treatment paradigms. This represents a high-risk, high-reward long-term growth opportunity (7-12 years), with the potential to address a critical oncology market segment.
What Opportunities Does LJPC Have?
- Successful advancement of pipeline candidates (TP-6076, TP-271, TP-2846) into later-stage clinical trials and commercialization.
- Expansion of GIAPREZA and XERAVA market share through increased adoption and new indications.
- Addressing the growing global threat of multidrug-resistant bacteria with novel antibiotics.
- Potential for new licensing or collaboration agreements to further develop and commercialize assets.
What Threats Does LJPC Face?
- Clinical trial failures or delays for pipeline candidates.
- Intense competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and potential for non-approval of new drugs.
- Market access and reimbursement challenges for existing and future products.
- Development of superior or cheaper alternative therapies by competitors.
What Are LJPC's Competitive Advantages?
- **Proprietary Products**: Ownership of GIAPREZA and XERAVA, which are approved and commercialized, provides established revenue streams and market presence.
- **Specialized Therapeutic Focus**: Concentration on critical care and life-threatening diseases creates a niche market with high barriers to entry due to stringent regulatory requirements and complex clinical development.
- **Pipeline of Novel Candidates**: Early-stage development of unique compounds like TP-6076, TP-271, and TP-2846 targets areas of high unmet medical need, potentially leading to future proprietary assets.
- **Licensing Partnerships**: Strategic agreements with companies like Everest Medicines and PAION AG facilitate broader market access and shared development costs, leveraging external expertise and resources.
What Does LJPC Do?
La Jolla Pharmaceutical Company, incorporated in 1989 and based in Waltham, Massachusetts, is a biotechnology firm dedicated to the development and commercialization of therapies designed to improve patient outcomes in severe, life-threatening conditions. The company's core commercial offerings include GIAPREZA (angiotensin II), a potent vasoconstrictor indicated to increase blood pressure in adults experiencing septic or other distributive shock, a critical condition often requiring immediate and effective intervention. Complementing this, La Jolla Pharmaceutical also markets XERAVA (eravacycline), a tetracycline class antibacterial specifically indicated for the treatment of complicated intra-abdominal infections in adult patients. These commercialized products are supplied to hospitals and other healthcare organizations primarily within the United States. Beyond its marketed portfolio, La Jolla Pharmaceutical maintains an active early-stage clinical and preclinical development pipeline. This pipeline includes TP-6076, an intravenous fluorocycline derivative targeting multidrug-resistant gram-negative bacteria; TP-271, an IV and oral fluorocycline formulation for respiratory diseases caused by bacterial biothreats, antibiotic-resistant pathogens, and community-acquired bacterial pneumonia; and TP-2846, an intravenous tetracycline for acute myeloid leukemia. The company has strategically entered into license agreements to expand the reach of its products, notably with Everest Medicines Limited for the development and commercialization of XERAVA, and with PAION AG for the commercialization of both GIAPREZA and XERAVA. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc., continuing its mission to address unmet medical needs in critical care.
What Products and Services Does LJPC Offer?
- Develops and commercializes therapies for life-threatening diseases.
- Offers GIAPREZA, a vasoconstrictor for increasing blood pressure in septic or distributive shock.
- Provides XERAVA, an antibacterial for complicated intra-abdominal infections.
- Sells its commercial products to hospitals and healthcare organizations in the United States.
- Conducts early-stage clinical and preclinical development for new drug candidates.
- Develops TP-6076 for multidrug-resistant gram-negative bacteria.
- Develops TP-271 for respiratory diseases caused by bacterial biothreats and resistant pathogens.
- Develops TP-2846 for acute myeloid leukemia.
- Engages in licensing agreements for product development and commercialization, such as with Everest Medicines and PAION AG.
How Does LJPC Make Money?
- Generates revenue through the direct sale of its commercialized pharmaceutical products, GIAPREZA and XERAVA, to healthcare institutions.
- Utilizes licensing agreements to expand the development and commercialization reach of its products in various territories or for specific indications.
- Invests in research and development to discover and advance new drug candidates through clinical trials, aiming for future commercialization.
- Focuses on high-value therapeutic areas in critical care and infectious diseases, where unmet medical needs allow for premium pricing.
What Industry Does LJPC Operate In?
La Jolla Pharmaceutical Company operates within the dynamic and research-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by significant R&D investments, long development cycles, and high regulatory hurdles, but also by the potential for substantial returns from successful drug commercialization. The broader healthcare market is driven by an aging global population, increasing prevalence of chronic and life-threatening diseases, and continuous advancements in medical science. La Jolla Pharmaceutical specifically targets critical care and infectious diseases, areas with ongoing unmet medical needs, particularly concerning conditions like septic shock and multidrug-resistant bacterial infections. The competitive landscape is intense, featuring both large pharmaceutical corporations and numerous smaller biotechnology firms vying for market share with innovative therapies. La Jolla Pharmaceutical's position is defined by its commercialized products, GIAPREZA and XERAVA, which serve established niches, and its early-stage pipeline, which aims to address emerging threats like antibiotic resistance and specific oncology indications. The company's licensing agreements also highlight a strategy to leverage partnerships for broader market access and development.
Who Are LJPC's Key Customers?
- Hospitals and critical care units requiring treatments for septic or distributive shock.
- Healthcare organizations and clinics treating patients with complicated intra-abdominal infections.
- Infectious disease specialists and surgeons utilizing advanced antibacterial therapies.
- Oncologists and hematologists, potentially in the future, for acute myeloid leukemia treatments.
- Government agencies or public health bodies, potentially for biothreat-related therapies.
How La Jolla Pharmaceutical Company Is Valued
Relative to its peer group, LJPC's quantitative score of 63/100 is below the peer average of 76/100.
Company Profile
La Jolla Pharmaceutical Company operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO George Tidmarsh. LJPC has traded publicly since 1994.
ROE -25%Key Financial Metrics
Return on equity for La Jolla Pharmaceutical Company stands at -25.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.4%, showing how much profit it generates from its asset base. LJPC trades at a trailing price-to-earnings ratio of 10.76, below the Healthcare sector average of ~23x. A current ratio of 3.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.3%, the inverse of the P/E and a quick read on earnings relative to price.
LJPC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has turned positive, with discussions highlighting the company's innovative approaches and recent advancements in its product pipeline.
- Analysts are noting a shift in market perception, with growing interest in the therapeutic areas LJPC is targeting, which could lead to increased investor interest.
- The company has recently made strategic partnerships that enhance its market position and could lead to accelerated growth in the coming months.
Bear Case
- Despite recent positive sentiment, there are lingering concerns about the company's financial stability and its ability to sustain operations without additional funding.
- The competitive landscape in the biotech sector is fierce, with many companies vying for attention, which could dilute LJPC's market share and impact its growth.
- Some community members express skepticism about the long-term viability of LJPC's business model, citing challenges in commercialization of its therapies.
- Recent regulatory hurdles have raised questions about the timeline for product approvals, potentially delaying revenue generation and impacting investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
LJPC Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Jun 13, 2022
LJPC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LJPC.
Price Targets
Wall Street price target analysis for LJPC.
LJPC MoonshotScore
What does this score mean?
The MoonshotScore rates LJPC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: George Tidmarsh
Chief Executive Officer
George Tidmarsh serves as the Chief Executive Officer of La Jolla Pharmaceutical Company, overseeing the strategic direction and operational management of the biotechnology firm. His role involves guiding the company's efforts in developing and commercializing therapies for life-threatening diseases. While specific details regarding his prior career history, educational background, and previous roles are not provided in the available data, his leadership is central to managing the company's 61 employees and its portfolio of commercial products and pipeline assets.
Track Record: Under George Tidmarsh's leadership, La Jolla Pharmaceutical Company has continued to advance its mission of addressing critical medical needs. His tenure has seen the ongoing commercialization of key products like GIAPREZA and XERAVA, which are vital for patients with septic shock and complicated intra-abdominal infections. He is responsible for guiding the strategic development of the company's early-stage pipeline, including candidates targeting multidrug-resistant bacteria and acute myeloid leukemia, ensuring the company's future growth trajectory.
La Jolla Pharmaceutical Company Healthcare Stock: Key Questions Answered
What does La Jolla Pharmaceutical Company do?
La Jolla Pharmaceutical Company is a biotechnology firm focused on developing and commercializing therapies for life-threatening diseases. The company's primary commercial products are GIAPREZA, a vasoconstrictor used to increase blood pressure in adults with septic or distributive shock, and XERAVA, an antibacterial for complicated intra-abdominal infections. These products are sold to hospitals in the United States. Additionally, La Jolla maintains an early-stage pipeline with candidates like TP-6076 for multidrug-resistant bacteria, TP-271 for respiratory pathogens, and TP-2846 for acute myeloid leukemia, aiming to address significant unmet medical needs.
What revenue streams does La Jolla Pharmaceutical Company have in healthcare?
La Jolla Pharmaceutical Company generates its revenue primarily through the direct sales of its two commercialized products: GIAPREZA and XERAVA. GIAPREZA contributes revenue from its use as a vasoconstrictor in critical care settings for septic or distributive shock patients. XERAVA generates revenue through its application as a tetracycline-class antibacterial for complicated intra-abdominal infections. Both products are sold to hospitals and other healthcare organizations within the United States. Furthermore, the company benefits from licensing agreements, such as those with Everest Medicines Limited and PAION AG, which facilitate the development and commercialization of XERAVA and GIAPREZA in various markets, potentially providing additional revenue streams through royalties or upfront payments.
What is La Jolla Pharmaceutical Company's drug pipeline status?
La Jolla Pharmaceutical Company's drug pipeline consists of several early-stage clinical and preclinical candidates. TP-6076 is an intravenous fluorocycline derivative currently in early development for the treatment of certain multidrug-resistant gram-negative bacteria, addressing a critical global health challenge. TP-271 is another fully synthetic fluorocycline, available in both IV and oral formulations, being developed for respiratory diseases caused by bacterial biothreats, antibiotic-resistant public health pathogens, and community-acquired bacterial pneumonia. Lastly, TP-2846 is an intravenous tetracycline formulation in early development for the treatment of acute myeloid leukemia, a severe form of blood cancer. All these candidates are in the initial phases of research and development, indicating a long pathway to potential commercialization.
What are the key factors to evaluate for LJPC?
La Jolla Pharmaceutical Company (LJPC) holds an AI score of 63/100 (moderate). P/E: 10.8x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does LJPC data refresh on this page?
LJPC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LJPC's recent stock price performance?
La Jolla Pharmaceutical Company (LJPC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercialized products GIAPREZA and XERAVA addressing critical medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LJPC overvalued or undervalued right now?
La Jolla Pharmaceutical Company (LJPC) trades at 10.8x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LJPC?
Before investing in La Jolla Pharmaceutical Company (LJPC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company's status as a subsidiary of Innoviva, Inc. as of August 22, 2022, means its direct stock trading status and independent financial reporting may have changed. Financial metrics (P/E, margins, Beta) are provided for LJPC as a distinct entity, and the analysis proceeds on that basis. Specific details on CEO background and track record are limited to available source data.